Sugi Predict

Sugi Predict / Compounds / SCHEMBL126525

SCHEMBL126525

SCHEMBL126525

Nc1ccc2c(n1)CCO2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 2/20 0.46
▸ MAPT P10636 3/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ PRKCI P41743 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAP3K14 Q99558 1/20 0.33
▸ CD274 Q9NZQ7 1/20 0.32
▸ NOS2 P35228 2/20 0.31
▸ NOS3 P29474 1/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ ITGB2 P05107 1/20 0.31
▸ ICAM1 P05362 1/20 0.31
▸ ITGAL P20701 1/20 0.31
▸ PLAU P00749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29618341 1.00 DYRK1A (0.46) DYRK1AMAPTRAB9ASMN1; SMN2PRKCI
SCHEMBL21935993 0.79 DYRK1A (0.35) DYRK1AMAPTRAB9ASMN1; SMN2PRKCI
SCHEMBL15435737 0.75 DYRK1A (0.39) DYRK1AMAPTRAB9ASMN1; SMN2PRKCI
SCHEMBL30848471 0.75 DYRK1A (0.35) DYRK1AMAPTRAB9ASMN1; SMN2PRKCI
SCHEMBL21333142 0.75 DYRK1A (0.35) DYRK1AMAPTRAB9ASMN1; SMN2PRKCI
SCHEMBL25768673 0.75 DYRK1A (0.35) DYRK1AMAPTRAB9ASMN1; SMN2PRKCI
SCHEMBL8103788 0.75 DYRK1A (0.36) DYRK1AMAPTRAB9ASMN1; SMN2PRKCI
SCHEMBL30540459 0.73 MAP3K14 (0.55) DYRK1AMAPTRAB9ASMN1; SMN2PRKCI
SCHEMBL23649681 0.73 MAP4K1 (0.38) DYRK1AMAPTALDH1A1GAANOS2
SCHEMBL30042104 0.73 MAP4K1 (0.38) DYRK1AMAPTALDH1A1GAANOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236619-A1 FUSED BICYCLIC COMPOUND CONTAINING PYRROLINONE CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-07-24 — — US disclosed
EP-4566612-A2 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES Recurium IP Holdings, LLC (US) 2025-06-11 — — EP disclosed
EP-3762385-B1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS LLC (US) 2025-02-12 — — EP disclosed
EP-4484434-A1 FUSED BICYCLIC COMPOUND CONTAINING PYRROLINONE Chia Tai Tianqing Pharmaceutical Group Co., Ltd (CN) 2025-01-01 — — EP disclosed
US-20240391924-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2024-11-28 — — US disclosed
CN-117720541-A Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones 里科瑞尔姆IP控股有限责任公司 2024-03-19 — — CN disclosed
CN-117285532-A Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones 里科瑞尔姆IP控股有限责任公司 2023-12-26 — — CN disclosed
CN-111902413-B Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones 里科瑞尔姆IP控股有限责任公司 2023-10-17 — — CN disclosed
WO-2023160577-A1 FUSED BICYCLIC COMPOUND CONTAINING PYRROLINONE 正大天晴药业集团股份有限公司 2023-08-31 — — WO disclosed
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 — — US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 — — US disclosed
US-20100029707-A1 TRICYCLIC COMPOUND AND MEDICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-04 — — US disclosed
US-20100029707-A1 TRICYCLIC COMPOUND AND MEDICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-04 — — US disclosed
US-20100029707-A1 TRICYCLIC COMPOUND AND MEDICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-04 — — US disclosed
US-20090233924-A1 Quinazoline derivatives ASTRAZENECA AB (SE) 2009-09-17 — — US disclosed
EP-2100895-A1 TRICYCLIC COMPOUND AND MEDICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-09-16 — — EP disclosed
EP-2100895-A1 TRICYCLIC COMPOUND AND MEDICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-09-16 — — EP disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 — — EP disclosed
US-20090036474-A1 Quinazoline derivatives for use against cancer PLE PATRICK 2009-02-05 — — US disclosed
WO-2008063625-A2 PYRIDINE COMPOUNDS AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 DYRK1A 1346/4885MAPT 3292/4885RAB9A 2732/4885
US-20090036474-A1 Quinazoline derivatives for use against cancer AQP3, AQP1, F12 DYRK1A 561/4885MAPT 3649/4885RAB9A 166/4885
US-20090233924-A1 Quinazoline derivatives AQP1, PGF, F12 DYRK1A 477/4885MAPT 3010/4885RAB9A 180/4885
US-20100029707-A1 TRICYCLIC COMPOUND AND MEDICAL USE THEREOF MTNR1A, MTNR1B, AHR DYRK1A 3624/4885MAPT 3911/4885RAB9A 4380/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DYRK1A 27/4885MAPT 1236/4885RAB9A 3462/4885
US-20240391924-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI DYRK1A 2828/4885MAPT 2838/4885RAB9A 870/4885
US-20250236619-A1 FUSED BICYCLIC COMPOUND CONTAINING PYRROLINONE WEE1, PPIF, WEE2 DYRK1A 3834/4885MAPT 2780/4885RAB9A 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.